Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Account Payables (2016 - 2021)

Lexaria Bioscience's Change in Account Payables history spans 7 years, with the latest figure at -$5223.0 for Q4 2021.

  • For Q4 2021, Change in Account Payables fell 118.34% year-over-year to -$5223.0; the TTM value through Aug 2022 reached -$5223.0, up 90.23%, while the annual FY2022 figure was -$5223.0, 90.23% up from the prior year.
  • Change in Account Payables for Q4 2021 was -$5223.0 at Lexaria Bioscience, down from $3899.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $119621.0 in Q1 2021 and bottomed at -$243169.0 in Q2 2017.
  • The 5-year median for Change in Account Payables is $1130.5 (2018), against an average of -$16399.6.
  • The largest annual shift saw Change in Account Payables crashed 2857.33% in 2017 before it soared 2259.44% in 2019.
  • A 5-year view of Change in Account Payables shows it stood at -$17672.0 in 2017, then skyrocketed by 178.08% to $13799.0 in 2018, then crashed by 178.96% to -$10896.0 in 2019, then surged by 361.39% to $28481.0 in 2020, then crashed by 118.34% to -$5223.0 in 2021.
  • Per Business Quant, the three most recent readings for LEXX's Change in Account Payables are -$5223.0 (Q4 2021), $3899.0 (Q3 2021), and -$205482.0 (Q2 2021).